Metacurum Biotech AB – Novel antibody treatment for metastatic cancers

MetaCurUm Biotech is developing a novel antibody treatment for metastatic cancers. The company´s drug development program is focused on transforming growth factor-beta (TGFβ) driven cancers, with the aim to optimize the treatment paradigms in aggressive forms of cancer with high unmet medical need such as prostate, lung, kidney, and endometrial cancer.

Read more

Medsens AB – exact real time prostate cancer diagnosis

By combining two different methods, Medsens AB aimed to offer a whole new tool for realtime microdiagnostics during prostate cancer surgery. Medsens, based on the work of Olof Lindahl och Kerstin Ramser, received support from UBI for three years. The company is put on hold but the research is ongoing.

Read more

Betulaceae Pharmaceuticals – improved quality of life during cancer

Our project goals aim at increased survival, improved quality of life and less suffering for cancer patients. Our novel chemical entities (NCE) can prevent over-activation of certain signaling pathways and are based on existing pharmaceuticals that are well tolerable and easy to produce. This will be a first in class drug with little side effects (known drug class), addressing cancer induced cachexia and suppression of the immune system.

Read more

Hiloprobe AB – improved colorectal cancer diagnostics

HiloProbe was a research-based company in the field of cancer diagnostics. HiloProbe developed ColoNode® – a biomarker test for the accurate detection and characterization of cancer cells in the lymph nodes of colorectal cancer patients. At the beginning of 2025, HiloProbe shut down its operations.

Read more